On August 29, 2023, the U.S. Department of Health and Human Services (HHS) submitted a letter to the U.S. Drug Enforcement Agency (DEA) proposing a shift in cannabis’ classification under the federal Controlled Substances Act (CSA). This recommendation follows less than a year from President Biden’s directive to federal officials to reassess cannabis’ categorization under federal law.
Currently, cannabis sits as a Schedule I substance – a classification reserved for drugs with no currently accepted medical use and a high potential for abuse. The proposal by the HHS suggests reclassifying cannabis as a Schedule III substance. Such a reclassification would acknowledge that the drug has a potential for abuse less than drugs in Schedules I and II, that it currently has accepted medical use in treatment in the United States, and that abuse of the substance may lead to moderate or low physical dependency or high psychological dependency.
The question that now remains to be answered is: Will the DEA agree to this proposed reclassification?
This reclassification proposal and its implications are discussed in detail by legal experts from Sheppard Mullin Richter & Hampton LLP in their recent analysis “Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree?” published on JD Supra. They examine potential outcomes of the HHS proposal, the implications for businesses operating in the cannabis industry, and the changes it could bring to federal enforcement actions should it be accepted.
A decision by the DEA on this proposed reclassification could greatly impact the regulatory landscape surrounding cannabis, legal implications for businesses and indeed, its recreational and medicinal uses. Thus, it will undoubtedly be an issue closely watched by legal professionals in the field.